Global Glycated Albumin Market 2016 – DIAZYME, Abnova, LifeSpan, Exocell, Leadman, BSBE
Diabetes afflicts an increasing number of people worldwide each year. Proper blood glucose control is essential in preventing complications associated with diabetes, such as neuropathy, nephropathy and retinopathy.
Glycation is the result of a sugar molecule, such as fructose or glucose, bonding to a protein or lipid molecule without the controlling action of an enzyme. It is a haphazard process that impairs the functioning of biomolecules. The high levels of glucose present in diabetes meatus results in increased glycation of all proteins, including, albumin. Measurement of the amount of the glycation reaction resulting from the combination of glucose with free amino groups in proteins present in the blood is used to monitor the level of glucose that has generally been present in body fluids over a preceding period.
Thus serum glycated albumin assay can be used to determine the current level of glycation of albumin, the most abundant plasma protein. Hence, the gycated albumin assay may be used as a marker of glycemic control in diabetes and reflects glycemic control over the precious 2 to 4 weeks.
Scope of the Report:
This report focuses on the Glycated Albumin in Global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
Market Segment by Manufacturers
Asahi Kasei Pharma
Request For Sample Report: http://www.fiormarkets.com/report-detail/16722/request-sample
Market Segment by Regions
North America (USA, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America, Middle East and Africa
Market Segment by Type
Glycated Albumin (Human)
Glycated Albumin (Animal)
Market Segment by Applications
Hospitals and Clinics
There are 13 Chapters to deeply display the global Glycated Albumin market report.